Opus Schedules Phase 3 Trial for OPGx-LCA5 Gene Therapy in Q4 2026

Opus announced its OPGx-LCA5 gene therapy for Leber Congenital Amaurosis type 5 (LCA5) is slated to begin a Phase 3 clinical trial in the fourth quarter of 2026. The company provided pipeline updates on its retinal disease programs, highlighting progress in addressing inherited vision disorders. The OPGx-LCA5 program targets a rare genetic retinal disorder. Additionally, Opus detailed progress for OPGx-RPGR, a gene therapy for X-linked retinitis pigmentosa (XLRP), which is currently in Phase 1/2 clinical trials. Opus also noted plans to file an Investigational New Drug (IND) application for OPGx-AAV-RPGR, another XLRP candidate. The company continues IND-enabling studies for OPGx-PDE6b, a gene therapy for autosomal recessive retinitis pigmentosa, underscoring its focus on developing treatments for various inherited retinal diseases.